Company intelligence / Profile preview
Celloram Inc.
Cleveland, Ohio, United Statescelloram.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Celloram is developing multiple preclinical assets including CLM-022 (licensed to Genfit), which has shown promising results in preclinical studies for Acute-on-Chronic Liver Failure (ACLF) by suppressing inflammasome complex formation, reducing IL-1β secretion, and mitigating pyroptosis.
- Therapeutic areas
- GastroenterologyOncologyImmunologyMetabolic Disorders
- Modalities
- Small moleculesCell therapyTherapeutic vaccine
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Genfit (CLM-022 licensing deal in 2023)
Beyond the preview
Go deeper on Celloram Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celloram Inc..